MeiraGTx Holdings plc (MGTX) stock
MGTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 13/3065% below fair value
$8.32−0.14 (-1.65%)
Close on Nov 18, 2026Market cap $799.08MP/E 11.7Yield –
MeiraGTx revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
MeiraGTx's revenue for the twelve months ending Jun 30, 2026 was $397.50M, up 948.3% year over year. For fiscal 2025 it was $81.39M, up 144.6% from the year before. The highest annual figure on record is $81.39M in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $81.39M | +144.6% |
| FY2024 | Dec 31, 2024 | $33.28M | +137.4% |
| FY2023 | Dec 31, 2023 | $14.02M | -12.0% |
| FY2022 | Dec 31, 2022 | $15.92M | -57.8% |
| FY2021 | Dec 31, 2021 | $37.70M | +142.2% |
| FY2020 | Dec 31, 2020 | $15.56M | +17.1% |
| FY2019 | Dec 31, 2019 | $13.29M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $321.43M | +8608.6% |
| Q1 FY2026 | Mar 31, 2026 | $293.00K | -84.8% |
| Q4 FY2025 | Dec 31, 2025 | $75.36M | +252.3% |
| Q3 FY2025 | Sep 30, 2025 | $410.00K | -96.2% |
| Q2 FY2025 | Jun 30, 2025 | $3.69M | +1208.9% |
| Q1 FY2025 | Mar 31, 2025 | $1.93M | +176.3% |
| Q4 FY2024 | Dec 31, 2024 | $21.39M | +948.5% |
| Q3 FY2024 | Sep 30, 2024 | $10.91M | +113.8% |
| Q2 FY2024 | Jun 30, 2024 | $282.00K | -92.0% |
| Q1 FY2024 | Mar 31, 2024 | $697.00K | -79.1% |
| Q4 FY2023 | Dec 31, 2023 | $2.04M | -57.6% |
| Q3 FY2023 | Sep 30, 2023 | $5.10M | -52.6% |
| Q2 FY2023 | Jun 30, 2023 | $3.54M | -37.2% |
| Q1 FY2023 | Mar 31, 2023 | $3.33M | -84.2% |
| Q3 FY2022 | Sep 30, 2022 | $4.82M | -30.7% |
| Q2 FY2022 | Jun 30, 2022 | $10.76M | +110.3% |
| Q1 FY2022 | Mar 31, 2022 | $5.63M | +22.6% |
| Q4 FY2021 | Dec 31, 2021 | $21.04M | +455.5% |
| Q3 FY2021 | Sep 30, 2021 | $6.95M | +36.4% |
| Q2 FY2021 | Jun 30, 2021 | $5.12M | +106.8% |
| Q1 FY2021 | Mar 31, 2021 | $4.60M | +9.1% |
| Q4 FY2020 | Dec 31, 2020 | $3.79M | -45.4% |
| Q3 FY2020 | Sep 30, 2020 | $5.09M | +42.1% |
| Q2 FY2020 | Jun 30, 2020 | $2.47M | +24.8% |
| Q1 FY2020 | Mar 31, 2020 | $4.21M | +436.3% |
| Q4 FY2019 | Dec 31, 2019 | $6.94M | – |
| Q3 FY2019 | Sep 30, 2019 | $3.58M | – |
| Q2 FY2019 | Jun 30, 2019 | $1.98M | – |
| Q1 FY2019 | Mar 31, 2019 | $784.96K | – |
See a number that looks wrong?